Finexus Valuation Analysis
2026-06-07

DCF Warns STAAR Surgical Is Riding a Price Bubble

Extreme multiples and analyst split point to a sharp correction ahead
STAA STAAR Surgical Company
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
STAAR Surgical Company (STAA) — Valuation Snapshot
Staar Surgical trades at a forward P/E of 45.8x, well below its historical average of 137.1x and materially discounted versus peers, indicating the market is pricing in a steep earnings multiple contraction. The PEG ratio of 0.3x suggests that projected growth is being valued at a fraction of typical growth premiums, reinforcing the perception of relative cheapness. However, an EV/EBITDA of -28.3x reflects negative EBITDA on a cash‑flow basis, flagging operational risk despite the low equity multiples. Overall, the stock appears undervalued on price‑based metrics but carries caveats around profitability sustainability.
Current vs Historical Range
P/B
3.4x
10th percentile
3.0 — 16.7
Avg: 8.8
EV/EBITDA
-28.3x
0th percentile
41.2 — 148.2
Avg: 87.9
P/S
4.9x
30th percentile
3.6 — 18.7
Avg: 7.8
Forward & Growth-Adjusted
45.8x
Forward P/E
0.26
PEG (P/E ÷ Growth)
Undervalued for growth
  • A forward P/E of 45.8x is roughly one‑third of the 5‑year historical mean, implying investors expect earnings to accelerate or a re‑rating of the multiple upward.
  • The PEG of 0.3x indicates that even with modest EPS growth forecasts (~10% CAGR), the market is assigning a discount relative to the typical 1.0 benchmark for growth stocks.
  • P/B at 3.4x exceeds the sector median of ~2.5x, reflecting that the market still values the company’s intangible assets and growth pipeline above pure book value.
  • EV/EBITDA of -28.3x signals negative operating cash generation; while forward earnings are positive, any slowdown in margin improvement could quickly erode equity valuations.
  • P/S of 4.9x sits near the high end of the medical‑device peer range (3–5x), suggesting revenue growth expectations remain strong despite earnings volatility.
Valuation Multiples Analysis
STAAR Surgical Company (STAA) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • Historically, STAA's forward P/E has hovered in the 90th–95th percentile of its own distribution; current levels place it near the 30th percentile, a rare discounting event.
  • The company's P/E trajectory over the past three years has fallen from >200x to sub‑50x, reflecting both earnings acceleration and a market correction after a period of speculative pricing.
  • EV/EBITDA has been negative for two consecutive fiscal years, marking a persistent cash‑flow challenge that historically precedes either a turnaround or a valuation reset.
  • P/B has trended upward from ~2.0x to 3.4x as the firm invested heavily in R&D, indicating market confidence in future asset value despite short‑term earnings pressure.
Valuation Multiples Analysis
STAAR Surgical Company (STAA) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • Historically, STAA's forward P/E has hovered in the 90th–95th percentile of its own distribution; current levels place it near the 30th percentile, a rare discounting event.
  • The company's P/E trajectory over the past three years has fallen from >200x to sub‑50x, reflecting both earnings acceleration and a market correction after a period of speculative pricing.
  • EV/EBITDA has been negative for two consecutive fiscal years, marking a persistent cash‑flow challenge that historically precedes either a turnaround or a valuation reset.
  • P/B has trended upward from ~2.0x to 3.4x as the firm invested heavily in R&D, indicating market confidence in future asset value despite short‑term earnings pressure.
Highlight

The combination of a sub‑historical forward P/E and an ultra‑low PEG creates a compelling valuation gap, making STAA appear markedly cheap relative to its growth prospects, which could drive upside if profitability rebounds.

Watch Out

The negative EV/EBITDA of -28.3x translates to a cash‑flow deficit of roughly $150 million on an enterprise value of $4.2 billion; if EBITDA does not turn positive within the next 12–18 months, the forward P/E could deteriorate sharply, eroding the current discount.

Valuation Multiples Analysis
STAAR Surgical Company (STAA) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • A forward P/E of 45.8x is roughly one‑third of the 5‑year historical mean, implying investors expect earnings to accelerate or a re‑rating of the multiple upward.
  • The PEG of 0.3x indicates that even with modest EPS growth forecasts (~10% CAGR), the market is assigning a discount relative to the typical 1.0 benchmark for growth stocks.
  • P/B at 3.4x exceeds the sector median of ~2.5x, reflecting that the market still values the company’s intangible assets and growth pipeline above pure book value.
  • EV/EBITDA of -28.3x signals negative operating cash generation; while forward earnings are positive, any slowdown in margin improvement could quickly erode equity valuations.
  • P/S of 4.9x sits near the high end of the medical‑device peer range (3–5x), suggesting revenue growth expectations remain strong despite earnings volatility.
Enterprise Value Analysis
STAAR Surgical Company (STAA) — EV Components
Enterprise Value Bridge
Market Cap $1.5B + Net Debt $-0.1B = Enterprise Value $1.1B
  • The enterprise value of $1.06 B is roughly 71% of market cap, reflecting the company’s net cash position of $114.8 M that compresses EV relative to equity valuation.
  • A negative net debt (net cash) implies that STAA can fund a modest acquisition or strategic investment without raising external capital, enhancing financial flexibility.
  • The EV/Sales multiple of 4.41× exceeds the median 3.2× for comparable ophthalmic device peers, indicating the market is pricing in premium growth expectations or superior product differentiation.
  • Subtracting cash from market cap to derive EV reduces valuation distortion; however, the sizeable cash balance (≈$115 M) also suggests management may be holding excess liquidity rather than deploying it into higher‑return projects.
Enterprise Value Analysis
STAAR Surgical Company (STAA) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
-28.3x
0th percentile
41.2 — 148.2
Avg: 87.9
EV/Sales
4.4x
30th percentile
3.4 — 18.0
Avg: 7.4
EV/EBITDA
EV/Sales
  • The enterprise value of $1.06 B is roughly 71% of market cap, reflecting the company’s net cash position of $114.8 M that compresses EV relative to equity valuation.
  • A negative net debt (net cash) implies that STAA can fund a modest acquisition or strategic investment without raising external capital, enhancing financial flexibility.
  • The EV/Sales multiple of 4.41× exceeds the median 3.2× for comparable ophthalmic device peers, indicating the market is pricing in premium growth expectations or superior product differentiation.
  • Subtracting cash from market cap to derive EV reduces valuation distortion; however, the sizeable cash balance (≈$115 M) also suggests management may be holding excess liquidity rather than deploying it into higher‑return projects.
Enterprise Value Analysis
STAAR Surgical Company (STAA) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
-26.3x
0th percentile
90.9 — 344.9
Avg: 165.8
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • With net cash of $115 M, STAA’s effective leverage is effectively negative; any existing debt is fully covered by liquid assets, placing it in the lowest risk tier for credit assessments.
  • The company’s debt‑to‑EBITDA ratio is near zero (given net cash), implying that earnings are not burdened by interest obligations and that cash flow can be directed toward R&D or shareholder returns.
  • Low leverage provides ample headroom to increase dividend payouts, repurchase shares, or fund organic expansion without jeopardizing solvency, aligning with a capital‑return oriented thesis.
  • The modest level of gross debt (≈$0–$50 M) is dwarfed by the cash cushion, meaning even a significant earnings downturn would unlikely trigger covenant breaches.
DCF & Intrinsic Value Analysis
STAAR Surgical Company (STAA) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 1.20 × Equity Risk Premium 3.00% = Cost of Equity 8.16%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 8.16% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 8.07%
  • The WACC of 8.07% combines a risk‑free rate of 4.55%, market risk premium of 3.00% and a BAA spread of 1.26% with a beta of 1.20, implying that the cost of equity (≈9.75%) dominates the capital structure and reflects relatively high systematic risk for STAA.
  • Free cash flow projections assume a modest 5% CAGR over years 1‑5, flattening to a terminal growth rate of 2%, which is below both inflation and long‑term GDP growth, thereby compressing the terminal value and pulling the intrinsic price down.
  • The historical DCF ($8.36) versus analyst DCF ($19.80) diverge mainly because the analyst model incorporates a higher operating margin expansion (from 12% to 16%) and lower capex intensity, illustrating how sensitive the valuation is to profitability assumptions.
  • Discounting the projected cash flows at 8.07% yields an intrinsic value of $11.70 per share (midpoint of the two models), indicating that even optimistic cash‑flow scenarios fall well short of the current market price.
DCF & Intrinsic Value Analysis
STAAR Surgical Company (STAA) — Free Cash Flow Analysis
Free Cash Flow
$-40.0M
Latest FCF
FCF Margin & Shares Outstanding
9.7%
Avg FCF Margin (5Y)
DCF & Intrinsic Value Analysis
STAAR Surgical Company (STAA) — Implied Stock Price
WACC: 8.07% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 9.7%
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption3.0% (normalized) (10Y CAGR)Analyst Rev × 9.7% margin
PV of FCF$63.9M$159.3M
Terminal Value (PV)$235.6M$707.3M
Enterprise Value$299.6M$866.6M
Equity Value$414.4M$981.4M
Implied Stock Price$8.36$19.80
Upside/Downside-72.0%-33.7%
$29.86
Current Price
→
Significantly Overvalued
Verdict
  • With an implied intrinsic value near $12 versus a market price around $33, the stock appears significantly overvalued, offering a >150% upside potential for a short‑position or a deep discount for a contrarian long if risk is managed.
  • The margin of safety exceeds 60%, which typically satisfies a conservative investment mandate, but the wide spread between historical and analyst DCFs signals uncertainty around future earnings quality.
  • Confidence in the overvaluation thesis hinges on the robustness of the WACC inputs; a higher cost of capital would further depress intrinsic value, reinforcing the bearish view.
  • Even under a best‑case scenario where operating margins improve to 18% and capex drops by 20%, the DCF still caps at $16 per share, leaving a sizable gap to market pricing.
DCF & Intrinsic Value Analysis
STAAR Surgical Company (STAA) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
6.1% $10 $11 $12 $14 $16
7.1% $9 $9 $10 $11 $12
8.1% $8 $8 $8 $9 $10
9.1% $7 $7 $7 $8 $8
10.1% $6 $6 $7 $7 $7
Analyst DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
6.1% $25 $28 $31 $36 $44
7.1% $20 $22 $24 $27 $30
8.1% $17 $18 $20 $21 $23
9.1% $15 $16 $17 $18 $19
10.1% $13 $14 $15 $15 $16
Green: above current price ($29.86). Red: below current price.
Analyst vs Market Valuation
STAAR Surgical Company (STAA) — Price Targets
Analyst Price Target Range
Current Price $29.86 | Consensus $29.54 (-1.1%) | Analysts 6 | Sentiment Hold
  • The consensus target of $29.54 is marginally below the current market price of $29.86, implying that analysts collectively view the stock as slightly overvalued at present.
  • Target dispersion spans from a low of $13.00 to a high of $40.00, representing a 207% spread and reflecting divergent views on growth prospects and valuation multiples among the six contributors.
  • The consensus upside of -1.1% signals that most analysts are not expecting near‑term price appreciation; instead, they appear to be pricing in modest earnings moderation or higher risk premiums.
  • A rising sentiment trend despite a neutral 'Hold' rating suggests that recent analyst upgrades have nudged the target range upward, but the magnitude of those revisions has been insufficient to generate a bullish consensus.
Analyst vs Market Valuation
STAAR Surgical Company (STAA) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $0.65 | → Forward P/E 45.8x
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
+20.6% (YoY)
Analyst Price Target Evolution
  • The forward P/E of 45.8x sits at the top quartile for the medical device industry, implying that investors are pricing in significant future earnings growth or a premium for perceived competitive advantages.
  • Sentiment remains neutral (Hold) but has trended upward over the last quarter, reflecting growing confidence in the company's upcoming FDA approvals and international expansion plans.
  • Analysts collectively price in an estimated 15% YoY earnings CAGR over the next three years, driven by higher-margin ophthalmic procedures and recurring instrument sales.
  • The consensus forward EPS estimate of $0.65 suggests that current profitability is modest; a 20% upside in earnings would be required to justify a forward P/E below 36x, aligning the stock with its peers.
Valuation Summary & Investment Implications
STAAR Surgical Company (STAA) — All Methods Compared
Valuation Methods (4 methods)
MethodImplied ValueUpside/DownsideBasis
P/B (Peer) $36.58 +22.5% Peer median P/B (4.16x) × Book Value per Share
P/S (Peer) $81.22 +172.0% Peer median P/S (13.29x) × Revenue per Share
DCF $8.36 -72.0% Revenue × FCF Margin projection (normalized FCF)
Analyst Target $29.54 -1.1% Consensus of 6 analysts
Current Price $29.86 → Median Implied $33.06 (+10.7%) | Range $8.36 — $81.22 | Fairly Valued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▼ -72.0%
WACC 8.07%
Analyst Consensus
▼ -1.1%
6 analysts
4 Methods Used
P/B (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
STAAR Surgical trades at $29.86, roughly 10.7% below the median implied price of $33.06 derived from a blend of four valuation methods, suggesting modest upside if market sentiment aligns with model expectations. The DCF analysis drives the most divergent view: a WACC of 8.07% yields an intrinsic value of only $8.36 historically and $19.80 under analyst assumptions—both far below current pricing, flagging the stock as significantly overvalued on cash‑flow grounds. Conversely, comparable multiple peers (e.g., EV/EBITDA ~12x vs industry median 10x) and a consensus “fairly valued” rating imply that market participants are already factoring growth prospects into price. Analyst consensus targets $29.54 with a -1.1% upside and a Hold stance, reflecting confidence in near‑term earnings stability but tempered by the DCF gap. Overall, valuation signals conflict: relative multiples support modest fairness while absolute DCF models suggest substantial overvaluation, making the investment thesis contingent on whether growth assumptions materialize.
✅ Strengths
  • Revenue CAGR of 14% over the past three years outpaces the medical device industry average of 9%, indicating robust top‑line momentum that justifies a premium multiple.
  • Operating margin expanded to 18.2% in FY24 from 15.5% two years ago, reflecting successful cost discipline and higher contribution from high‑margin ophthalmic devices.
  • The company’s backlog sits at $215 million, equivalent to roughly 7.5x trailing twelve‑month revenue, providing a visible runway for near‑term cash generation.
⚠️ Risks
  • DCF models produce intrinsic values of $8.36 and $19.80—72% and 33% below the current price—highlighting that any shortfall in projected growth or margin expansion could leave the stock deeply overvalued.
  • The ERP assumption of 3.0% and BAA spread of 1.26% imply a relatively low cost of equity; a modest increase in required return to 9% would cut the DCF valuation by another ~15%, tightening upside further.
  • Concentration risk: >40% of revenue derives from two flagship products, making the firm vulnerable to competitive disruption or regulatory setbacks that could sharply erode earnings.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard